Waitlist mortality and transplant free survival in Hispanic patients listed for liver transplant using the UNOS database.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Historique:
received: 05 10 2020
revised: 02 12 2020
accepted: 03 12 2020
pubmed: 15 1 2021
medline: 14 1 2022
entrez: 14 1 2021
Statut: ppublish

Résumé

After the implementation of "Share 35", several concerns arose such as the potential to increase travel distance, costs, and decreased liver availability. These elements could have a negative impact on waitlist outcomes among ethnic minorities. We aimed to determine waitlist survival after the implementation of the Share 35 policy in non-Hispanic white and Hispanic patients. We identified non-Hispanic whites and Hispanics who were listed for liver transplantation from June 18th, 2013 to June 18, 2018. We excluded pediatric patients, patients with acute hepatic necrosis, re-transplants, multiorgan transplant, living donor, and exception cases. The primary outcome was death or removal from the waitlist due to clinical deterioration. We used competing risk analysis to compare waitlist survival between the two groups. There were 23,340 non-Hispanic whites and 4938 Hispanics listed for transplant. On competing risk analysis, Hispanic patients had a higher risk of being removed from the waitlist for death or clinical deterioration compared to their counterpart (SHR 1.23, 95% CI 1.13-1.34; P < 0.001). After the implementation of Share 35, disparities are still present and continue to negatively impact outcomes in minority populations especially Hispanic patients.

Identifiants

pubmed: 33444852
pii: S1665-2681(21)00003-X
doi: 10.1016/j.aohep.2021.100304
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100304

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Daniela Goyes (D)

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: dgoyes@bidmc.harvard.edu.

Christopher J Danford (CJ)

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: cdanford@bidmc.harvard.edu.

John Paul Nsubuga (JP)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: jnsubuga@bidmc.harvard.edu.

Alan Bonder (A)

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: abonder@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH